ClinicalTrials.gg
CompletedNCT02474082PRIMEUpdated Oct 27, 2017Results posted

Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

A Phase 3 interventional study of Secukinumab and Fumaric acid in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 32 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
17th of 54
202 · median 124
Started
2015
with 6 others
Phase 3
24 of 54
none open now
Registered
26th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 17th largest by enrollment, is one of 7 that started in 2015, is one of 24 in phase 3, and was the 26th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

This is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are candidates for systemic therapy. The study consists of 2 periods: a screening period of at least one week and up to four weeks, and a treatment period of 24 weeks. During the screening period eligibility of the patients is confirmed. Eligible patients are randomized 1:1 to treatment arm A or B at week 0. Patients in treatment arm A receive secukinumab administered at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20 and are followed up for assessments of the study endpoints until week 24. Patients in treatment arm B receive daily doses of Fumaderm® p.o.. Safety and efficacy measurements of secukinumab and Fumaderm® will be performed throughout the study and up to week 24.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women must be at least 18 years of age at the time of screening
  • Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization Patients with moderate to severe plaque psoriasis who are candidates for systemic therapy as defined at randomization by:
  • PASI score of >10
  • Affected body surface area (BSA) > 10%
  • DLQI >10
  • Inadequate response, intolerance or to topical psoriasis treatment as documented in the patient's medical history or reported by the patient or determined by the investigator at screening.

Exclusion criteria

Exclusion Criteria (abbreviated):

  • Previous systemic treatment of plaque psoriasis or known for systemic therapy at baseline
  • Ongoing use of other prohibited psoriasis and non-psoriasis treatment.
  • active infections or infestations, chronic, recurrent or latent infections or infestations
  • Patients with severe liver diseases
  • Patients with severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers
  • Patients with severe kidney diseases or serum creatinine above 1 x
  • Patients with known hematological disease or lab abnormalities
  • Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of (if necessary)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.

    Biological: Secukinumab

  • Active comparator
    Fumaric acid (initial and maintenance therapy)

    Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.

    Drug: Fumaric acid

Interventions

  • BiologicalSecukinumab

    Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection

    Also known as: AIN457

  • DrugFumaric acid

    Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)

    Also known as: Fumarate, Fumaric acid, Fumaric acid esters

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24

    PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 75 responders were participants who achieved \>=75% improvement (reduction) in PASI score compared to baseline.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 50 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 50 responders were participants who achieved \>=50% improvement (reduction) in PASI score compared to baseline.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  2. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 1, 2, 3, 4, 6, 8, 12, 16 and 20

    PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 75 responders were participants who achieved \>=75% improvement (reduction) in PASI score compared to baseline.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16 and 20

  3. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 90 responders were participants who achieved \>=90% improvement (reduction) in PASI score compared to baseline.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  4. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 100 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 100 responders were participants who achieved complete clearance of psoriasis (PASI=0).

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  5. Body Surface Area (BSA) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    The Body surface area (BSA) affected by plaque-type psoriasis was the total of percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head = 0.1, trunk = 0.3, upper limbs = 0.2, lower limbs = 0.4). The resulting four percentages were added to estimate the total BSA affected by plaque-type psoriasis.

    Time frame: Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  6. Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 50 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 50 responders were participants who achieved \>=50% improvement (reduction) in NPASI score compared to baseline.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  7. Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 75 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 75 responders were participants who achieved \>=75% improvement (reduction) in NPASI score compared to baseline.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  8. Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 90 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 90 responders were participants who achieved \>=90% improvement (reduction) in NPASI score compared to baseline.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  9. Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 100 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 100 responders were participants who PASI 100 responders were participants who achieved complete clearance of psoriasis.

    Time frame: Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  10. Number of Participants With Investigator's Global Assessment (IGA Mod 2011) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    IGA mod 2011 is a global static severity rating scale referring exclusively to the participant's disease state at the time of the assessments and don't attempt comparison with participant's any previous disease states at baseline or visit. IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. Scores used were: 0/Clear: no signs of psoriasis, Post-inflammatory hyperpigmentation may be present; 1/almost clear: Normal to pink coloration of lesions/no thickening/no to minimal focal scaling; 2/Mild: Pink to light red coloration/just detectable to mild thickening/predominantly fine scaling; 3/Moderate: Dull bright red, clearly distinguishable erythema/clearly distinguishable to moderate thickening/moderate scaling; 4/Severe: Bright to deep dark red coloration/severe thickening with hard edges/severe or coarse scaling covering almost all or all lesions.

    Time frame: Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  11. Percentage of Participants With IGA Mod. 2011 0/1-response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject's disease state at the time of the assessments, and does not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe. IGA 0/1 responders: who achieved score of 0/1 and improved by at least 2 points on the IGA scale compared to baseline.

    Time frame: Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  12. Dermatology Life Quality Index (DLQI) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral. The measure was self-administered and included domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item had four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" was also a valid response and was scored as 0. The DLQI total score was a sum of the 10 questions. Scores ranged from 0 to 30, with higher scores indicating greater impairment in health related quality of life.

    Time frame: Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  13. Percentage of Participants With DLQI 0/1 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

    DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral. The measure was self-administered and included domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item had four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" was also a valid response and was scored as 0. The DLQI total score was a sum of the 10 questions. Scores ranged from 0 to 30, with higher scores indicating greater impairment in health related quality of life. DLQI 0/1 response was the achievement of a DLQI score of 0 or 1.

    Time frame: Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

  14. Percentage of Participants With Short Form 36 (SF-36) Response at Week 4, 16 and 24

    SF-36 is a generic indicator of health status for use in population surveys and evaluative studies of health policy. The SF-36 included 36 items in a Likert-type or forced-choice format measured on eight dimensions. The scores for each domain range from 0 to 100, with high scores indicating a better status. SF-36 responder is defined as subject reaching at least an improvement of minimum important difference (MID). The SF-36 measure dimensions and their MID includes: * Physical Functioning:4.3 * Role-Physical: 3.4 * Bodily Pain: 6.2 * General Health: 7.2 * Vitality: 6.2 * Social Functioning: 6.9 * Role-Emotional: 4.5 * Mental Health: 6.2 Two component scores and their MID which were derived from the above mentioned 8 domains includes-: * Physical component summary: 3.4 * Mental component summary: 4.6

    Time frame: Week 4, 16 and 24

07

Results

Posted Oct 27, 2017

Participant flow

Participant flow — Overall Study
MilestoneSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Started10597
Full analysis set (fas)10595
Completed9943
Not completed654
Withdrew: Adverse event232
Withdrew: Withdrawal of informed consent111
Withdrew: Lost to follow-up22
Withdrew: Dose tapering not achieved04
Withdrew: Participant/guardian decision12
Withdrew: Non-compliance with study treatment02
Withdrew: Protocol deviation01

Outcome measures

PrimaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24

PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 75 responders were participants who achieved \>=75% improvement (reduction) in PASI score compared to baseline.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 2489.5233.68
Statistical analysis
  • Secukinumab vs Fumaric Acid (Initial and Maintenance Therapy) · Regression, Logistic · p = <.0001 · Odds ratio (or): 16.61 · 95% CI 7.79 to 35.40
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 50 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 50 responders were participants who achieved \>=50% improvement (reduction) in PASI score compared to baseline.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 50 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 19.51.1
Week 237.16.3
Week 363.810.5
Week 481.914.7
Week 693.328.4
Week 8)96.241.1
Week 1297.156.8
Week 1698.160.0
Week 2098.161.1
Week 2498.161.1
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 1, 2, 3, 4, 6, 8, 12, 16 and 20

PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 75 responders were participants who achieved \>=75% improvement (reduction) in PASI score compared to baseline.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 1, 2, 3, 4, 6, 8, 12, 16 and 20
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 100
Week 25.70
Week 324.80
Week 447.61.1
Week 669.52.1
Week 880.08.4
Week 1287.621.1
Week 1688.627.4
Week 2088.636.8
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 90 responders were participants who achieved \>=90% improvement (reduction) in PASI score compared to baseline.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 100
Week 21.90
Week 32.90
Week 417.10
Week 632.40
Week 846.71.1
Week 1263.82.1
Week 1668.68.4
Week 2075.214.7
Week 2475.218.9
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 100 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

PASI score is an average degree of severity of signs in head \[H\], trunk \[T\], upper limbs \[U\] and lower limbs \[L\], assessed separately for erythema \[E\], thickening (plaque elevation, induration) \[I\], and scaling (desquamation) \[D\]. Area \[A\] covered by lesions on each body region was estimated as a percentage (%) of total area of that particular body region and was assigned a score of 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. The head and neck, upper limbs, trunk and lower limbs correspond to approximately 10%, 20%, 30% and 40% of the body surface area, respectively. PASI score was calculated as: PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU + 0.3(ET+IT+DT) AT + 0.4(EL+IL+DL) AL. PASI scores can range from 0 (no signs) to a maximum of 72.0. PASI 100 responders were participants who achieved complete clearance of psoriasis (PASI=0).

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 100 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 100
Week 200
Week 300
Week 43.80
Week 67.60
Week 815.20
Week 1228.60
Week 1637.10
Week 2041.00
Week 2443.83.2
SecondaryBody Surface Area (BSA) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

The Body surface area (BSA) affected by plaque-type psoriasis was the total of percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head = 0.1, trunk = 0.3, upper limbs = 0.2, lower limbs = 0.4). The resulting four percentages were added to estimate the total BSA affected by plaque-type psoriasis.

Time frame:
Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Mean · Percentage of area
Body Surface Area (BSA) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of areaSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 123.8 ± 12.8223.2 ± 14.11
Week 220.1 ± 12.2522.5 ± 14.37
Week 317.0 ± 11.9522.1 ± 14.33
Week 413.0 ± 11.9321.6 ± 14.12
Week 69.8 ± 11.1219.7 ± 13.52
Week 87.6 ± 10.1917.8 ± 12.65
Week 125.2 ± 9.1213.7 ± 11.60
Week 163.7 ± 6.7211.4 ± 11.52
Week 202.6 ± 5.779.2 ± 11.87
Week 242.9 ± 6.437.9 ± 9.92
SecondaryPercentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 50 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 50 responders were participants who achieved \>=50% improvement (reduction) in NPASI score compared to baseline.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 50 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 11.84.1
Week 23.68.2
Week 35.410.2
Week 47.112.2
Week 619.610.2
Week 823.28.2
Week 1241.112.2
Week 1651.810.2
Week 2062.518.4
Week 2467.918.4
SecondaryPercentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 75 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 75 responders were participants who achieved \>=75% improvement (reduction) in NPASI score compared to baseline.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 75 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 11.80
Week 21.82.0
Week 35.42.0
Week 47.12.0
Week 68.92.0
Week 817.92.0
Week 1228.62.0
Week 1630.42.0
Week 2044.66.1
Week 2453.64.1
SecondaryPercentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 90 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 90 responders were participants who achieved \>=90% improvement (reduction) in NPASI score compared to baseline.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 90 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 11.80
Week 21.80
Week 300
Week 43.60
Week 63.60
Week 87.12.0
Week 1214.32.0
Week 1621.42.0
Week 2026.84.1
Week 2435.74.1
SecondaryPercentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 100 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

NAPSI was used to assess psoriatic nail involvement in participants with nail psoriasis. NAPSI score was calculated as total of nail matrix and nail bed score, ranging from 0-8 per nail. Total NAPSI score ranges from 0 to 80 for all fingernails. Each nail was divided with imaginary horizontal and longitudinal lines into quadrants. Each nail was given a score of 0 - 4 for nail matrix and nail bed psoriasis 0-4 (0: for none, 1: for 1 quadrant, 2: for 2 quadrants, 3: for 3 quadrants, 4: for all 4 quadrants), based on presence of any feature of nail psoriasis in that quadrant. Nail matrix psoriasis feature includes: pitting, leukonychia red spots in lunula, crumbling. Nail bed psoriasis feature includes: onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma). NPASI 100 responders were participants who PASI 100 responders were participants who achieved complete clearance of psoriasis.

Time frame:
Baseline, Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Nail Psoriasis Severity Index (NAPSI) 100 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 11.80
Week 200
Week 300
Week 43.60
Week 63.60
Week 85.42.0
Week 1210.72.0
Week 1619.62.0
Week 2019.62.0
Week 2423.22.0
SecondaryNumber of Participants With Investigator's Global Assessment (IGA Mod 2011) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

IGA mod 2011 is a global static severity rating scale referring exclusively to the participant's disease state at the time of the assessments and don't attempt comparison with participant's any previous disease states at baseline or visit. IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. Scores used were: 0/Clear: no signs of psoriasis, Post-inflammatory hyperpigmentation may be present; 1/almost clear: Normal to pink coloration of lesions/no thickening/no to minimal focal scaling; 2/Mild: Pink to light red coloration/just detectable to mild thickening/predominantly fine scaling; 3/Moderate: Dull bright red, clearly distinguishable erythema/clearly distinguishable to moderate thickening/moderate scaling; 4/Severe: Bright to deep dark red coloration/severe thickening with hard edges/severe or coarse scaling covering almost all or all lesions.

Time frame:
Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Global Assessment (IGA Mod 2011) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
ParticipantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 1: Clear00
Week 1: Almost Clear00
Week 1: Mild188
Week 1: Moderate6558
Week 1: Severe2228
Week 2: Clear00
Week 2: Almost Clear60
Week 2: Mild3815
Week 2: Moderate4956
Week 2: Severe1220
Week 3: Clear00
Week 3: Almost Clear141
Week 3: Mild5118
Week 3: Moderate3551
Week 3: Severe519
Week 4: Clear40
Week 4: Almost Clear311
Week 4: Mild4621
Week 4: Moderate1946
Week 4: Severe316
Week 6: Clear90
Week 6: Almost Clear422
Week 6: Mild3926
Week 6: Moderate744
Week 6: Severe110
Week 8: Clear170
Week 8: Almost Clear524
Week 8: Mild2932
Week 8: Moderate234
Week 8: Severe25
Week 12: Clear310
Week 12: Almost Clear4911
Week 12: Mild1935
Week 12: Moderate419
Week 12: Severe02
Week 16: Clear380
Week 16: Almost Clear4212
Week 16: Mild1535
Week 16: Moderate411
Week 16: Severe01
Week 20: Clear430
Week 20: Almost Clear3617
Week 20: Mild1824
Week 20: Moderate28
Week 20: Severe01
Week 24: Clear454
Week 24: Almost Clear3621
Week 24: Mild1315
Week 24: Moderate57
Week 24: Severe01
SecondaryPercentage of Participants With IGA Mod. 2011 0/1-response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject's disease state at the time of the assessments, and does not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe. IGA 0/1 responders: who achieved score of 0/1 and improved by at least 2 points on the IGA scale compared to baseline.

Time frame:
Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With IGA Mod. 2011 0/1-response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 100
Week 25.70
Week 313.31.1
Week 434.31.1
Week 650.52.1
Week 866.74.2
Week 1277.112.6
Week 1680.014.7
Week 2079.020.0
Week 2481.028.4
SecondaryDermatology Life Quality Index (DLQI) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral. The measure was self-administered and included domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item had four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" was also a valid response and was scored as 0. The DLQI total score was a sum of the 10 questions. Scores ranged from 0 to 30, with higher scores indicating greater impairment in health related quality of life.

Time frame:
Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Mean · Score on a scale
Dermatology Life Quality Index (DLQI) at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Score on a scaleSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 113.9 ± 5.8616.3 ± 6.44
Week 210.5 ± 6.2215.3 ± 6.99
Week 38.4 ± 5.9614.6 ± 7.01
Week 46.6 ± 5.1313.8 ± 7.23
Week 65.3 ± 5.7912.4 ± 7.24
Week 84.2 ± 4.7511.0 ± 7.16
Week 123.1 ± 4.418.8 ± 7.10
Week 162.7 ± 3.956.8 ± 6.05
Week 202.5 ± 3.845.9 ± 5.67
Week 242.0 ± 3.585.4 ± 5.56
SecondaryPercentage of Participants With DLQI 0/1 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24

DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral. The measure was self-administered and included domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item had four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" was also a valid response and was scored as 0. The DLQI total score was a sum of the 10 questions. Scores ranged from 0 to 30, with higher scores indicating greater impairment in health related quality of life. DLQI 0/1 response was the achievement of a DLQI score of 0 or 1.

Time frame:
Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With DLQI 0/1 Response at Week 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Week 100
Week 23.81.1
Week 37.60
Week 419.02.1
Week 630.54.2
Week 840.06.3
Week 1257.110.5
Week 1659.014.7
Week 2064.815.8
Week 2471.425.3
SecondaryPercentage of Participants With Short Form 36 (SF-36) Response at Week 4, 16 and 24

SF-36 is a generic indicator of health status for use in population surveys and evaluative studies of health policy. The SF-36 included 36 items in a Likert-type or forced-choice format measured on eight dimensions. The scores for each domain range from 0 to 100, with high scores indicating a better status. SF-36 responder is defined as subject reaching at least an improvement of minimum important difference (MID). The SF-36 measure dimensions and their MID includes: * Physical Functioning:4.3 * Role-Physical: 3.4 * Bodily Pain: 6.2 * General Health: 7.2 * Vitality: 6.2 * Social Functioning: 6.9 * Role-Emotional: 4.5 * Mental Health: 6.2 Two component scores and their MID which were derived from the above mentioned 8 domains includes-: * Physical component summary: 3.4 * Mental component summary: 4.6

Time frame:
Week 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Short Form 36 (SF-36) Response at Week 4, 16 and 24
Percentage of participantsSecukinumabFumaric Acid (Initial and Maintenance Therapy)
Physical Component Summary Week 438.126.1
Mental component summary Week 441.236.4
Physical functioning scale Week 424.519.6
Role physical scale Week 444.223.7
Bodily pain scale Week 453.331.6
General health scale Week 432.421.1
Vitality scale Week 431.720.4
Social functioning scale Week 439.227.7
Role emotional scale Week 441.334.7
Mental health scale Week 433.332.6
Physical Component Summary Week 1652.639.8
Mental component summary Week 1663.946.6
Physical functioning scale Week 1636.331.5
Role physical scale Week 1652.936.6
Bodily pain scale Week 1663.845.3
General health scale Week 1638.222.1
Vitality scale Week 1645.223.7
Social functioning scale Week 1657.841.5
Role emotional scale Week 1656.743.2
Mental health scale Week 1654.342.1
Physical Component Summary Week 2457.743.2
Mental component summary Week 2463.950.0
Physical functioning scale Week 2438.231.5
Role physical scale Week 2452.937.6
Bodily pain scale Week 2464.849.5
General health scale Week 2441.221.1
Vitality scale Week 2448.129.0
Social functioning scale Week 2463.745.7
Role emotional scale Week 2454.841.1
Mental health scale Week 2453.338.9

Adverse events

Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse events are reported in this record from First Patient First Treatment until Last Patient Last Visit (up to 29 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab—4/105 (3.8%)75/105 (71.4%)
Fumaric Acid (Initial and Maintenance Therapy)—4/95 (4.2%)85/95 (89.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventSecukinumabFumaric Acid (Initial and Maintenance Therapy)
PSORIASISSkin and subcutaneous tissue disorders0/1052/95
ANAL HAEMORRHAGEGastrointestinal disorders0/1051/95
DIARRHOEAGastrointestinal disorders0/1051/95
PILONIDAL CYSTInfections and infestations0/1051/95
ASTHENIAGeneral disorders1/1050/95
CLAVICLE FRACTUREInjury, poisoning and procedural complications1/1050/95
DEHYDRATIONMetabolism and nutrition disorders1/1050/95
METASTASES TO CENTRAL NERVOUS SYSTEMNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1050/95
SMALL CELL LUNG CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1050/95
BRAIN OEDEMANervous system disorders1/1050/95
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSecukinumabFumaric Acid (Initial and Maintenance Therapy)
NASOPHARYNGITISInfections and infestations54/10540/95
DIARRHOEAGastrointestinal disorders7/10548/95
ABDOMINAL PAIN UPPERGastrointestinal disorders3/10537/95
FLUSHINGVascular disorders1/10534/95
LYMPHOPENIABlood and lymphatic system disorders2/10523/95
NAUSEAGastrointestinal disorders3/10520/95
EOSINOPHILIABlood and lymphatic system disorders1/10517/95
HEADACHENervous system disorders15/10515/95
ABDOMINAL PAINGastrointestinal disorders2/10511/95
PRURITUSSkin and subcutaneous tissue disorders7/1058/95

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SecukinumabFumaric Acid (Initial and Maintenance Therapy)Total
<=18 years000
Between 18 and 65 years9890188
>=65 years7714
Age, Continuous
Age, Continuous(years)SecukinumabFumaric Acid (Initial and Maintenance Therapy)Total
Mean43.2 ± 14.242.4 ± 13.242.8 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabFumaric Acid (Initial and Maintenance Therapy)Total
Female403777
Male6560125
08

Study locations

32 sites
  • Novartis Investigative Site
    Bad Bentheim, 48455, Germany
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Berlin, 10247, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13187, Germany
  • Novartis Investigative Site
    Berlin, 13578, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bochum, 44803, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Darmstadt, 64283, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Gera, 07548, Germany
  • Novartis Investigative Site
    Halle, 06108, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Lubeck, 23538, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Mannheim, 68167, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Osnabruck, 49074, Germany
  • Novartis Investigative Site
    Quedlinburg, 06484, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Selters, 56242, Germany
  • Novartis Investigative Site
    Stade, 21682, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2015
First posted
Jun 17, 2015
Start
Apr 2015
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results first posted
Oct 27, 2017
Last update
Oct 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02474082
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Apr 2015
Primary completion
Jun 2016
Completion
Jun 2016
Results posted
Oct 27, 2017
Last update
Oct 27, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion